STOCK TITAN

Adage discloses 2.53% Amylyx stake (NASDAQ: AMLX) in Schedule 13G/A

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Adage Capital Management, L.P. and related individuals report beneficial ownership of 2,777,055 shares of Amylyx Pharmaceuticals common stock, representing 2.53% of the outstanding shares. The shares are held with shared voting and dispositive power and reflect ownership of 5 percent or less of the class.

The filing is an amended Schedule 13G indicating a passive investment. The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Amylyx Pharmaceuticals.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Adage Capital Management, L.P.
Signature:/s/ Robert Atchinson
Name/Title:By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
Date:02/12/2026
Robert Atchinson
Signature:/s/ Robert Atchinson
Name/Title:Robert Atchinson, individually
Date:02/12/2026
Phillip Gross
Signature:/s/ Phillip Gross
Name/Title:Phillip Gross, individually
Date:02/12/2026

FAQ

What stake in Amylyx Pharmaceuticals (AMLX) does Adage report in this 13G/A?

Adage Capital Management and related filers report beneficial ownership of 2,777,055 shares of Amylyx Pharmaceuticals common stock, representing 2.53% of the outstanding class, based on 109,819,569 shares reported outstanding as of October 27, 2025.

Is Adage’s Amylyx (AMLX) position considered a passive investment?

Yes. The filers certify the Amylyx shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control, consistent with a passive Schedule 13G filing status.

Who are the reporting persons in the Amylyx (AMLX) Schedule 13G/A?

The reporting persons are Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross. They report beneficial ownership through investment management roles tied to Adage Capital Partners, L.P. and related general partner entities.

How much voting power does Adage report over Amylyx (AMLX) shares?

The reporting persons disclose 0 shares with sole voting power and 2,777,055 shares with shared voting power. They also report the same amount with shared dispositive power, indicating decisions are made collectively rather than individually.

Why does this Amylyx (AMLX) filing mention ownership of 5 percent or less?

The filing states that the reporting persons hold 5 percent or less of Amylyx’s common stock. Their disclosed 2.53% stake falls below key reporting thresholds, confirming they are not a 5% or greater beneficial owner at this time.

What date does this Amylyx (AMLX) Schedule 13G/A reflect for the reportable event?

The reportable event date is listed as December 31, 2025. The ownership percentage is calculated using 109,819,569 shares of Amylyx common stock outstanding as of October 27, 2025, as disclosed in the company’s Form 10-Q.
Amylyx Pharmaceuticals

NASDAQ:AMLX

AMLX Rankings

AMLX Latest News

AMLX Latest SEC Filings

AMLX Stock Data

1.58B
91.56M
9.5%
94.68%
9.43%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE